CA
NZ
UK
AU
IND
US
…
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Mereo BioPharma Group plc is a small clinical-stage biopharmaceutical company that acquires and develops therapeutics for oncology and rare diseases through in-licensing, clinical development and partnering. Long-term growth may be driven by positive clinical trial results, regulatory approvals and successful partnering or commercialization of pipeline assets, which could support upside if programs advance.
Material risks include clinical and regulatory setbacks, limited or no product revenue requiring additional financing, patent and competitive pressures, and operational or liquidity constraints that could delay or dilute development.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -36.09M | 14.24M | -166.45M | -41.12M | -37.31M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -34.20M | 12.72M | -163.63M | -34.84M | -32.03M |
| Selling general administrative | 19.54M | 15.93M | 21.22M | 15.91M | 12.50M |
| Gross profit | 2.44M | 18.56M | -15.95M | -23.73M | -22.70M |
| Reconciled depreciation | 0.73M | 0.64M | 1.60M | 1.58M | 0.04M |
| Ebit | -43.57M | -20.94M | -37.57M | -39.52M | -34.90M |
| Ebitda | -42.06M | -20.31M | -37.52M | -37.56M | -34.86M |
| Depreciation and amortization | 1.51M | 0.62M | 0.04M | 1.95M | 0.04M |
| Non operating income net other | - | - | - | - | 0.00M |
| Operating income | -43.57M | -20.94M | -37.57M | -39.52M | -35.21M |
| Other operating expenses | 43.57M | 57.40M | 37.57M | 39.52M | 35.21M |
| Interest expense | 3.36M | 4.00M | 6.38M | 3.50M | 2.36M |
| Tax provision | -1.90M | 1.52M | -2.82M | -6.27M | -5.28M |
| Interest income | 0.70M | 0.00M | 0.01M | 0.18M | 0.31M |
| Net interest income | -2.67M | -4.02M | -6.34M | -3.58M | -2.03M |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | -1.90M | 1.52M | -2.82M | -6.27M | -5.28M |
| Total revenue | 1.51M | 36.46M | 0.39M | -0.12M | 0.00M |
| Total operating expenses | 44.51M | 39.49M | 21.22M | 15.91M | 12.50M |
| Cost of revenue | -0.94M | 17.91M | 16.35M | 23.61M | 22.70M |
| Total other income expense net | 7.48M | 35.18M | -128.88M | -1.60M | -0.04M |
| Discontinued operations | - | - | - | - | 0.00M |
| Net income from continuing ops | -34.20M | 12.72M | -163.63M | -34.84M | -32.03M |
| Net income applicable to common shares | -34.20M | 12.72M | -163.63M | -34.84M | -32.03M |
| Preferred stock and other adjustments | - | - | - | - | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 66.50M | 88.08M | 126.42M | 62.95M | 86.45M |
| Intangible assets | 1.09M | 24.12M | 24.56M | 31.65M | 44.46M |
| Other current assets | 1.36M | - | 3.21M | 2.03M | 2.40M |
| Total liab | 15.96M | 26.21M | 38.41M | 77.92M | 46.19M |
| Total stockholder equity | 50.54M | 61.87M | 88.00M | -14.97M | 40.26M |
| Other current liab | 0.03M | 10.05M | 1.27M | 4.60M | 0.35M |
| Common stock | 2.77M | 1.88M | 1.75M | 1.02M | 0.29M |
| Capital stock | 2.77M | 1.88M | 1.75M | 1.02M | 0.29M |
| Retained earnings | -419.63M | -331.16M | -296.97M | -309.69M | -146.06M |
| Other liab | - | 0.31M | 9.74M | 52.05M | 1.62M |
| Cash | 57.42M | 56.33M | 94.30M | 23.47M | 16.35M |
| Total current liabilities | 9.49M | 24.68M | 12.54M | 8.56M | 29.88M |
| Current deferred revenue | 6.46M | - | 8.37M | - | 5.45M |
| Net debt | -51.47M | -43.56M | -77.54M | -5.53M | 16.07M |
| Short term debt | 0.65M | 11.55M | 0.62M | 0.64M | 17.73M |
| Short long term debt | - | 11.09M | - | - | 15.14M |
| Short long term debt total | 5.95M | 12.77M | 16.76M | 17.94M | 32.42M |
| Other stockholder equity | 484.88M | 253.25M | 246.32M | 160.48M | 138.71M |
| Property plant equipment | - | 1.83M | 2.53M | 1.57M | 11.56M |
| Total current assets | 63.76M | 62.13M | 99.32M | 29.73M | 30.43M |
| Net tangible assets | - | 37.75M | 63.44M | -46.62M | -4.20M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | 3.73M | 2.67M | 1.82M | 4.64M | 11.98M |
| Long term debt | 4.39M | - | 14.38M | 16.14M | 5.37M |
| Inventory | 1.25M | - | - | - | - |
| Accounts payable | 2.35M | 3.08M | 2.29M | 3.33M | 6.35M |
| Accumulated other comprehensive income | -17.48M | 137.91M | 136.90M | 133.22M | 47.32M |
| Common stock total equity | - | - | - | 1.02M | 0.29M |
| Non currrent assets other | - | - | - | - | 11.56M |
| Non current assets total | 2.74M | 25.95M | 27.09M | 33.22M | 56.01M |
| Capital lease obligations | 1.56M | 1.69M | 2.38M | 1.79M | 11.90M |
| Long term debt total | - | - | - | - | 14.69M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 1.50M | -0.42M | 1.50M | 43.30M | 0.25M |
| Change to liabilities | 1.13M | -1.26M | -3.55M | -6.73M | 1.60M |
| Total cashflows from investing activities | - | -0.42M | 1.50M | 43.30M | 0.25M |
| Net borrowings | -0.94M | -0.69M | 22.49M | -2.21M | 0.46M |
| Total cash from financing activities | -0.78M | 77.65M | 34.74M | -5.71M | -2.07M |
| Change to operating activities | - | - | - | - | 0.00M |
| Net income | -36.09M | 14.24M | -166.45M | -41.12M | -37.31M |
| Change in cash | -37.96M | 70.83M | 7.12M | -8.70M | -25.00M |
| Begin period cash flow | 94.30M | 23.47M | 16.35M | 25.04M | 50.04M |
| End period cash flow | 56.33M | 94.30M | 23.47M | 16.35M | 25.04M |
| Total cash from operating activities | -38.82M | -5.24M | -28.34M | -45.93M | -23.14M |
| Issuance of capital stock | 0.00M | 78.53M | 20.14M | 0.00M | 0.27M |
| Depreciation | 0.73M | 0.64M | 1.60M | 1.58M | 0.04M |
| Other cashflows from investing activities | - | 0.00M | 0.04M | 0.38M | 0.29M |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | 0.69M | -0.59M | 0.14M | -0.94M | 7.20M |
| Sale purchase of stock | - | 0.00M | 0.00M | -1.00M | -0.31M |
| Other cashflows from financing activities | 0.15M | -0.19M | 36.49M | -2.50M | -2.04M |
| Change to netincome | - | -16.76M | 137.10M | -5.00M | 6.45M |
| Capital expenditures | 0.01M | 0.54M | 0.02M | 0.02M | 0.04M |
| Change receivables | - | - | - | - | 0.00M |
| Cash flows other operating | - | - | - | - | 0.00M |
| Exchange rate changes | - | - | - | - | 0.00M |
| Cash and cash equivalents changes | - | - | - | - | 0.00M |
| Change in working capital | 1.82M | -1.84M | -3.41M | -7.67M | 2.41M |
| Stock based compensation | 3.86M | 3.30M | 1.56M | 1.64M | 2.19M |
| Other non cash items | -9.14M | 13.41M | 5.22M | -0.43M | 1.92M |
| Free cash flow | -38.83M | -5.77M | -28.36M | -45.95M | -23.17M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MREO Mereo BioPharma Group PLC ADR |
-0.01 3.42% |
0.30 | - | - | 38.15 | 7.55 | 33.00 | -12.67 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
One Cavendish Place, London, United Kingdom, W1G 0QF
44 33 3023 7300
33
| Name | Title | Year Born |
|---|---|---|
| Dr. Denise Scots-Knight Ph.D. | Co-Founder, CEO & Exec. Director | 1959 |
| Mr. Charles Sermon | Co-Founder, Gen. Counsel & Company Sec. | 1969 |
| Dr. Alastair MacKinnon M.D., MBBS | Co-Founder and Chief of Portfolio & Pipeline Strategy | 1970 |
| Dr. John P. Richard M.B.A., MBA | Co-Founder & Chief Bus. Officer | 1957 |
| Ms. Christine Fox CPA | Chief Financial Officer | 1981 |
| Dr. John A. Lewicki Ph.D. | Chief Scientific Officer | 1952 |
| Dr. Jackie Parkin | Therapy Area Head of Respiratory Endocrinology | NA |
| Ms. Alexandra Hughes-Wilson | Chief of Patient Access & Commercial Planning | 1971 |
| Dr. Suba Krishnan | Sr. VP of Clinical Devel. | NA |
| Dr. Fiona Bor | Head of Intellectual Property | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...